Compare OESX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OESX | IGC |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 33.8M |
| IPO Year | 2007 | N/A |
| Metric | OESX | IGC |
|---|---|---|
| Price | $14.74 | $0.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.50 | $4.13 |
| AVG Volume (30 Days) | 65.4K | ★ 496.5K |
| Earning Date | 11-05-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,947,000.00 | $1,106,000.00 |
| Revenue This Year | $6.83 | $3.54 |
| Revenue Next Year | $13.65 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $0.25 |
| 52 Week High | $18.60 | $0.50 |
| Indicator | OESX | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 50.11 |
| Support Level | $16.19 | $0.28 |
| Resistance Level | $18.60 | $0.36 |
| Average True Range (ATR) | 1.38 | 0.02 |
| MACD | -0.37 | 0.01 |
| Stochastic Oscillator | 12.07 | 68.46 |
Orion Energy Systems Inc is engaged in light-emitting diode lighting systems, wireless Internet of Things-enabled control solutions, project engineering, energy project management design, maintenance services, and turnkey electric vehicle charging stations and related installation services to commercial and industrial businesses, and federal and local governments, predominantly in North America. The group has three segments: the Orion lighting segment, the Orion maintenance segment, and the Orion electric vehicle charging segment. It generates the majority of its revenue from the Orion lighting segment, which develops and sells lighting products and provides construction and engineering services for Orion's commercial lighting and energy management systems.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.